Pharmstandard Announces Unaudited Sales Results for 1H 2010
OREANDA-NEWS. August 2, 2010. Pharmstandard (LSE: PHST LI, RTS: PHST RU), announces its unaudited IFRS sales results for the first 6 months 2010.
According to its unaudited report, Pharmstandard’s sales for the first 6 months of 2010 achieved RUR11,543 million and increased by 14.7% or RUR1,481 million compared to the sales of RUR 10,062 million for the first 6 months of 2009.
Pharmaceutical products sales contributed 97.8% while medical equipment and disposables sales contributed 2.2% of total Company sales.
Pharmaceutical products
The Company’s sales of pharmaceutical products for the first six months of 2010 increased by 15.4% and achieved RUR11,293 million compared to the sales of RUR9,789 million for the same period of 2009. The sales growth in absolute value achieved RUR1,504 million.
In the sales structure of pharmaceutical products 64.3% contributed by sales of pharmaceutical products owned by the Company and 35.7% contributed by sales of the 3rd parties products
The sales of the Company’s owned products for the first half of 2010 increased by 13.3% or by RUR853 million and achieved RUR7,265 million.
In the sales structure of Company’s owned products 78.1% contributed by the non-prescription products and 21.9% by the prescription products.
The sales of the Company’s owned non-prescription (OTC) products increased by 4.7% or by RUR255 million and achieved RUR5,677 million. The best selling products were Arbidol®, Pentalgin®, Afobasol®, Amixin®.
The sales of the Company’s owned prescription (Rx) products increased by 60.4% or by RUR598 million and achieved RUR1,588 million. The best selling products were Phosphoglive®, Combilipen®, Rastan®, Biosulin®.
The sales of the 3rd parties products increased by 18.7% or by RUR623 million and achieved RUR3,956 million compared to the same period of 2009. The best selling products were Velcade® (Bortezomib), Mildronate® (Meldonium), Coagil VII (Eptacog Alfa) and Pulmozyme® (Dornaze alfa).
The OJSC Pharmstandard and “Johnson & Johnson” LLC entered into mutual agreement and successfully realized the project to localize secondary packaging of the product Velcade® (INN Bortezomib) in production plant OJSC “Pharmstandard-UfaVITA”. The sales of the product in the first half of 2010 achieved RUR1,650 million.
The Company successfully launched first shipments of the product Coagil VII (INN Eptacog Alpha) for the amount of RUR 791 million. Coagil VII were developed in the frame of biotechnological project “Generium” established by OJSC Pharmstandard and CJSC “Lekko”. In December 2009 OJSC Pharmstandard has won the federal open auction in frame of the government program “7 nosologies” to deliver the product Coagil VII for the 10 months of 2010 for the amount of RUR 1,069 million (excluding VAT).
Medical equipment
The Company’s sales of medical equipment and disposables for the first six months 2010 decreased by RUR22 million or by 8.2% and achieved RUR251 million compared to RUR273 million in the first half of 2009.
OJSC Pharmstandard sales structure for the first 6 months 2010, million of RUR
|
|
1H 2010 (RUR mln) |
% of total sales |
1H 2009 (RUR mln) |
% of total sales |
Change (RUR mln) |
Change (%) |
|
Pharmaceutical products |
11,292.7 |
97.8% |
9,788.6 |
97.3% |
1,504.0 |
15.4% |
|
PHS owned products |
7,265.0 |
62.9% |
6,412.2 |
63.7% |
852.8 |
13.3% |
|
Non-prescription products |
5,676.9 |
49.2% |
5,422.2 |
53.9% |
254.7 |
4.7% |
|
Branded |
4,665.2 |
40.4% |
4,488.9 |
44.6% |
176.3 |
3.9% |
|
Non-branded |
1,011.7 |
8.8% |
933.3 |
9.3% |
78.4 |
8.4% |
|
Prescription products |
1,588.1 |
13.8% |
990.0 |
9.8% |
598.1 |
60.4% |
|
Branded |
1,351.2 |
11.7% |
883.4 |
8.8% |
467.8 |
53.0% |
|
Non-branded |
236.9 |
2.1% |
106.6 |
1.1% |
130.2 |
122.1% |
|
3rd parties products |
3,956.2 |
34.3% |
3,333.6 |
33.1% |
622.6 |
18.7% |
|
Velcade® |
1,649.6 |
14.3% |
2,278.1 |
22.6% |
-628.5 |
-27.6% |
|
Coagil VII |
790.6 |
6.8% |
0.0 |
0.0% |
790.6 |
- |
|
Pulmozyme® |
610.2 |
5.3% |
0.0 |
0.0% |
610.2 |
- |
|
Mildronate® |
554.7 |
4.8% |
673.6 |
6.7% |
-118.9 |
-17.7% |
|
Other 3rd parties products |
351.1 |
3.0% |
381.9 |
3.8% |
-30.8 |
-8.1% |
|
Other products |
71.5 |
0.6% |
42.8 |
0.4% |
28.7 |
66.9% |
|
Medical equipments |
250.7 |
2.2% |
273.3 |
2.7% |
-22.5 |
-8.2% |
|
Total group sales |
11,543.4 |
100.0% |
10,061.9 |
100.0% |
1,481.5 |
14.7% |
OJSC Pharmstandard sales structure for the first 6 months 2010 (without 3rd parties products), million of RUR
|
|
1H 2010 (RUR mln) |
% of total sales |
1H 2009 (RUR mln) |
% of total sales |
Change (RUR mln) |
Change (%) |
|
Pharmaceutical products |
7,336.5 |
96.7% |
6,455.0 |
95.9% |
881.4 |
13.7% |
|
PHS owned products |
7,265.0 |
95.8% |
6,412.2 |
95.3% |
852.8 |
13.3% |
|
Non-prescription products |
5,676.9 |
74.8% |
5,422.2 |
80.6% |
254.7 |
4.7% |
|
Branded |
4,665.2 |
61.5% |
4,488.9 |
66.7% |
176.3 |
3.9% |
|
Non-branded |
1,011.7 |
13.3% |
933.3 |
13.9% |
78.4 |
8.4% |
|
Prescription products |
1,588.1 |
20.9% |
990.0 |
14.7% |
598.1 |
60.4% |
|
Branded |
1,351.2 |
17.8% |
883.4 |
13.1% |
467.8 |
53.0% |
|
Non-branded |
236.9 |
3.1% |
106.6 |
1.6% |
130.2 |
122.1% |
|
Other products |
71.5 |
0.9% |
42.8 |
0.6% |
28.7 |
66.9% |
|
Medical equipments |
250.7 |
3.3% |
273.3 |
4.1% |
-22.5 |
-8.2% |
|
Total sales of owned products |
7,587.2 |
100.0% |
6,728.3 |
100.0% |
858.9 |
12.8% |
Комментарии